RT Journal Article
T1 Edoxaban treatment in a post-infarction experimental model
A1 Martínez-Fernández, Javier
A1 Almengló Buzón, Cristina
A1 Babarro, Borja
A1 Iglesias Rey, Ramón
A1 García-Caballero Parada, Tomás
A1 Fernández, Ángel L.
A1 Souto Bayarri, José Miguel
A1 González Juanatey, José Ramón
A1 Álvarez Castro, Ezequiel
K1 Edoxaban
K1 Acute myocardial infarction experimental model
K1 Cardiac remodelling after infarction
K1 Cardiac magnetic resonance imaging
K1 Post-infarction anticoagulant treatment
AB BackgroundThe sequelae of myocardial infarction (MI) require specific pharmacological therapy to minimise the post-MI remodelling, which in many cases evolves into cardiovascular complications. The aim of this study was to analyse the effect of edoxaban, an oral anticoagulant, on cardiac recovery in a rat model of permanent coronary artery ligation.MethodsAn experimental method to assess the post-MI remodelling in rats for 4 weeks, based on cardiac magnetic resonance imaging (MRI) and final histological analysis of the hearts was performed. The influence of daily oral treatment with edoxaban (20 mg/kg/day) for 28 days post-MI was analysed in comparison to vehicle.ResultsIn our model, edoxaban was shown to be safe and bleeding was observed in 1 of 10 animals. General physical recovery of the treated animals was shown by higher body weight recovery compared with non-treated animals (38.6 ± 2.9 vs. 29.9 ± 3.1 g, respectively, after 28 days). There was not a pronounced effect of edoxaban in post-MI cardiac remodelling, but mitigated fibrosis was observed by the reduced expression of vascular endothelial growth factor and tumour growth factor β1 in the peri-infarct zone.ConclusionsOur analysis provided the experimental basis to support the feasibility of MRI to study cardiac function and characterise myocardial scarring in a rat model. Overall data suggested the safety of edoxaban in the model, and compared to placebo, it showed a better post-MI recovery, probably by reducing fibrosis of the heart. Further research on mid-term cardiac recovery with edoxaban after MI is justified.
PB Elsevier
SN 0014-2999
YR 2024
FD 2024
LK http://hdl.handle.net/10347/32986
UL http://hdl.handle.net/10347/32986
LA eng
NO European Journal of Pharmacology Volume 962, 5 January 2024, 176216
DS Minerva
RD 24 abr 2026